These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31653805)

  • 1. Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.
    Nelson CN; Dombi E; Rosenblum JS; Miettinen MM; Lehky TJ; Whitcomb PO; Hayes C; Scott G; Benzo S; Widemann BC; Chittiboina P
    J Neurosurg; 2020 Nov; 133(5):1516-1526. PubMed ID: 31653805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
    Higham CS; Dombi E; Rogiers A; Bhaumik S; Pans S; Connor SEJ; Miettinen M; Sciot R; Tirabosco R; Brems H; Baldwin A; Legius E; Widemann BC; Ferner RE
    Neuro Oncol; 2018 May; 20(6):818-825. PubMed ID: 29409029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI.
    Ristow I; Kaul MG; Stark M; Zapf A; Riedel C; Lenz A; Mautner VF; Farschtschi S; Apostolova I; Adam G; Bannas P; Salamon J; Well L
    Neurooncol Adv; 2024; 6(1):vdae021. PubMed ID: 38468867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological outcomes and surgical complications in 221 spinal nerve sheath tumors.
    Safaee MM; Lyon R; Barbaro NM; Chou D; Mummaneni PV; Weinstein PR; Chin CT; Tihan T; Ames CP
    J Neurosurg Spine; 2017 Jan; 26(1):103-111. PubMed ID: 27472744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital.
    Guha D; Davidson B; Nadi M; Alotaibi NM; Fehlings MG; Gentili F; Valiante TA; Tator CH; Tymianski M; Guha A; Zadeh G
    J Neurosurg; 2018 Apr; 128(4):1226-1234. PubMed ID: 28686119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumor location, extent of resection, and neurofibromatosis status with clinical outcomes for 221 spinal nerve sheath tumors.
    Safaee M; Parsa AT; Barbaro NM; Chou D; Mummaneni PV; Weinstein PR; Tihan T; Ames CP
    Neurosurg Focus; 2015 Aug; 39(2):E5. PubMed ID: 26235022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant peripheral nerve sheath tumors of the spine: results of surgical management from a multicenter study.
    Chou D; Bilsky MH; Luzzati A; Fisher CG; Gokaslan ZL; Rhines LD; Dekutoski MB; Fehlings MG; Ghag R; Varga P; Boriani S; Germscheid NM; Reynolds JJ;
    J Neurosurg Spine; 2017 Mar; 26(3):291-298. PubMed ID: 27834629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities.
    Kresbach C; Dottermusch M; Eckhardt A; Ristow I; Paplomatas P; Altendorf L; Wefers AK; Bockmayr M; Belakhoua S; Tran I; Pohl L; Neyazi S; Bode H; Farschtschi S; Well L; Friedrich RE; Reuss D; Snuderl M; Hagel C; Mautner VF; Schüller U
    Neuro Oncol; 2023 Sep; 25(9):1644-1655. PubMed ID: 36866403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
    Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.